Empagliflozin 25mg

DRUG7 trials

Conditions

Body WeightDiabetes ComplicationsDiabetes MellitusDiabetes Mellitus, Type 1Diabetes Mellitus, Type IIHeart FailureHypoglycemic AgentsHyponatremia

Phase 1

Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin

NCT02854748

Chong Kun Dang PharmaceuticalDiabetes Mellitus, Type II

Start: 2016-08-31End: 2016-09-30Target: 30Updated: 2016-08-09

Pharmacokinetic Evaluation of Empagliflozin

CompletedNCT03059056

British University In EgyptDiabetes Mellitus

Start: 2017-02-02End: 2017-02-02Updated: 2017-02-23

Phase 2

Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study

CompletedNCT03202667

University Hospital, Basel, SwitzerlandHyponatremia, SIAD - Syndrome of Inappropriate Antidiuresis

Start: 2017-12-15End: 2021-12-06Updated: 2021-12-13

Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes

CompletedNCT03227484

University Hospital TuebingenBody Weight, PreDiabetes

Start: 2017-06-09End: 2019-11-18Updated: 2020-04-29

Phase 4

SGLT2 Inhibition in Combination With Diuretics in Heart Failure

CompletedNCT03226457

University of DundeeHeart Failure, Type 2 Diabetes Mellitus

Start: 2017-12-11End: 2019-01-09Updated: 2021-06-30

The Effects of Empagliflozin on Arterial Wall Characteristics

NCT03639545

University Medical Centre LjubljanaDiabetes Complications, Diabetes Mellitus, Type 1, Hypoglycemic Agents +1

Start: 2018-03-01End: 2019-01-30Target: 120Updated: 2018-08-21

Unknown Phase

Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin

CompletedNCT03510000

Samuel Lunenfeld Research Institute, Mount Sinai HospitalType1diabetes

Start: 2018-05-15End: 2019-11-21Updated: 2021-06-24

2026-08-01

Apelin and Copeptin Levels in Patients With Chronic SIAD Treated With Empagliflozin

Journal of the Endocrine Society2024-05-235 citations

OR2805 Plasma Sodium Increase Is Associated With An Increase In Bone Formation In Outpatients With Chronic SIAD—A Predefined Secondary Analysis Of The SANDx Trial

Journal of the Endocrine Society2023-10-01

An Increase in Plasma Sodium Levels Is Associated With an Increase in Osteoblast Function in Chronic SIAD

The Journal of Clinical Endocrinology & Metabolism2023-04-2517 citations

Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial

Journal of the American Society of Nephrology2022-11-1770 citations

180-OR: Empagliflozin Does Not Affect Pancreatic Fat Content and Insulin Secretion in Humans with Prediabetes

Diabetes2022-05-31

Eight weeks of empagliflozin does not affect pancreatic fat content and insulin secretion in people with prediabetes

Diabetes Obesity and Metabolism2022-04-2711 citations

No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects

Drug Design Development and Therapy2021-04-013 citations

Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure

Circulation2020-08-30239 citations

Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus

Cardiovascular Diabetology2018-12-0192 citations

Renal and Cardiovascular Effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial

BMJ Open2017-10-0144 citations